Technical Analysis for GRFS - Grifols, S.A.

Grade Last Price % Change Price Change
grade C 19.72 -0.40% -0.08
GRFS closed down 0.4 percent on Tuesday, February 19, 2019, on 1.6 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 27

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical GRFS trend table...

Date Alert Name Type % Chg
Feb 19 Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Feb 19 NR7 Range Contraction 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 19 Upper Bollinger Band Touch Strength 0.00%
Feb 15 MACD Bullish Centerline Cross Bullish -0.40%
Feb 15 Expansion Breakout Bullish Swing Setup -0.40%
Feb 15 Stochastic Reached Overbought Strength -0.40%
Feb 15 Above Upper BB Strength -0.40%
Feb 15 Overbought Stochastic Strength -0.40%
Feb 15 Up 3 Days in a Row Strength -0.40%

Older signals for GRFS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates in four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments and reagents for diagnostics, as well as blood bank products. This division serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals comprising parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. The company was formerly known as Probitas Pharma, S.A. and changed its name to Grifols, S.A. in 2005. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Healthcare Providers Antibody End Products Nutrition Products European Union Hemophilia Transfusion Medicine Ibex 35 In Vitro Diagnostics Plasma Products
Is GRFS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.97
52 Week Low 17.42
Average Volume 800,272
200-Day Moving Average 20.6531
50-Day Moving Average 18.8244
20-Day Moving Average 18.949
10-Day Moving Average 18.944
Average True Range 0.4856
ADX 13.65
+DI 32.6655
-DI 18.9461
Chandelier Exit (Long, 3 ATRs ) 18.3632
Chandelier Exit (Short, 3 ATRs ) 19.2968
Upper Bollinger Band 19.7756
Lower Bollinger Band 18.1224
Percent B (%b) 0.97
BandWidth 8.724471
MACD Line 0.0793
MACD Signal Line -0.0318
MACD Histogram 0.1111
Fundamentals Value
Market Cap 26.94 Billion
Num Shares 1.37 Billion
EPS 0.49
Price-to-Earnings (P/E) Ratio 40.24
Price-to-Sales 5.73
Price-to-Book 6.87
PEG Ratio 1.34
Dividend 0.33
Dividend Yield 1.67%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.09
Resistance 3 (R3) 20.08 19.95 20.03
Resistance 2 (R2) 19.95 19.86 19.95 20.01
Resistance 1 (R1) 19.84 19.80 19.89 19.84 19.99
Pivot Point 19.71 19.71 19.73 19.71 19.71
Support 1 (S1) 19.59 19.61 19.65 19.60 19.45
Support 2 (S2) 19.46 19.55 19.46 19.43
Support 3 (S3) 19.35 19.46 19.41
Support 4 (S4) 19.35